Gastric Inhibitory Polypeptide (3-42) (human) |
| Catalog No.GA21894 |
Le polypeptide inhibiteur gastrique (3-42) (humain) agit comme un antagoniste du récepteur du polypeptide insulinotrope dépendant du glucose (GIP), modérant la sécrétion d'insuline et les actions métaboliques du GIP in vivo.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1802086-25-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Gastric inhibitory polypeptide (3-42) represents the major physiological degradation product of gastric inhibitory polypeptide (GIP). It is generated by proteolytic processing of GIP by dipeptidyl peptidase IV (DPP IV).
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *